Total mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
Higher total dose radiotherapy (76.8 Gy over 6.4 weeks) showed no clear difference in total mortality compared with conventional/standard total dose radiotherapy (72 Gy); GRADE not reported.
1 finding from 1 review
HR 1.08 [0.69, 1.70]
1 study
GRADE not reported
Locoregional control · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
Higher total dose radiotherapy (76.8 Gy over 6.4 weeks) showed no clear difference in locoregional control compared with conventional/standard total dose radiotherapy (72 Gy); GRADE not reported.
1 finding from 1 review
HR 0.78 [0.55, 1.11]
1 study
GRADE not reported
Leaving the study early: insufficient response ‐ When compared with ultra low dose (<2 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
4 findings from 1 review
Show 1 more finding
Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in adverse effects: EPS: unspecified ‐ Versus low dose (greater than or… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in adverse effects: EPS: unspecified ‐ Versus standard‐lower dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower adverse effects: EPS: unspecified ‐ Versus high dose (greater than… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Prostate cancer · Adults (general population)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Prostate cancer: OR 1.04 (95% CI 0.98 to 1.09), not statistically significant. Umbrella review outcome-level evidence grade: Substantial effect unlikely.
1 finding from 1 review
Type 2 diabetes mellitus · Adults (general population)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Type 2 diabetes: OR 0.63 (95% CI 0.56 to 0.69), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
1 finding from 1 review
Sporadic colorectal adenoma recurrence · Adults (general population)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Sporadic colorectal adenoma recurrence: OR 0.87 (95% CI 0.57 to 1.33), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
Ischaemic heart disease · Adults (general population)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Ischaemic heart disease: HR 0.72 (95% CI 0.65 to 0.81), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
Breast cancer · Adults (general population)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Breast cancer (Premenopausal): RR 1.01 (95% CI 0.97 to 1.06), not statistically significant. Umbrella review outcome-level evidence grade: Substantial effect unlikely.
3 findings from 1 review
RR 1.01 [0.97, 1.06]
6 studies · 2890 participants
GRADE not reported
RR 0.99 [0.97, 1.01]
9 studies · 8766 participants
GRADE not reported
OR 0.55 [0.42, 0.71]
21 studies · 26317 participants
GRADE not reported
All cause mortality · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for All cause mortality, Patients with chronic kidney disease: RR 0.86 (95% CI 0.81 to 0.92), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
Metabolic syndrome (prevalent) · Adults (general population)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Metabolic syndrome (prevalent): OR 0.49 (95% CI 0.38 to 0.64), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
1 finding from 1 review